This part gets me excited...
"To give you an idea of the potential, there are probably 100m people in the developed world with OA who could use this drug. It needs to be taken yearly, which means it has a huge addressable market and repeat revenue. At $5k per treatment and just 10% of that market it would be over $25b in revenue. CSL does around $9b and is valued over $100b. Hence why we think Paradigm is the most asymmetric investment opportunity we can see."
Could PAR be the next CSL?, page-2
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.3¢ | $194.3K | 781.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 197100 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 75699 | 7 |
View Market Depth
| Last trade - 15.41pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |